Mosaic Therapeutics closes a $28 million Series A round
Mosaic Therapeutics, Ltd has closed a $28 million Series A funding round. Investment in this round was obtained from Syncona Investment Management, Ltd, and Cambridge Innovation Capital.
The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO.
The Series A funding will be used to further advance Mosaic Therapeutics’ targeted oncology pipeline for biomarker-stratified populations, advancing its core program through preclinical development to IND-supporting studies. The fund will also support recruitment efforts, build the company’s senior leadership, experimental biology, and computing teams.
Relationship of Mosaic Therapeutics with Welcome Sanger Institute also providing it with access to scientific expertise, infrastructure and biological assets.
Platform Mosaic Therapeutics
The Mosaic Therapeutics platform leverages research from Mathew Garnett’s Translational Cancer Genomics Laboratory at the Wellcome Sanger Institute. Garnett is a senior group leader at Sanger with more than 20 years of experience in genomics and cancer therapy. Previous achievements include the co-discovery of BRAF mutations in cancer and Werner’s Syndrome helicase as a target in MSI tumors.
Gladsden said: “I believe that Mosaic is ideally positioned to address the complexities of cancer, to find and develop targeted therapies that address areas of high unmet need. The people, platform, connections to world-leading genomics research institutes, and strong investor partnerships are truly best in class.”
Garnett added: “Mosaic is poised to lead the next wave of cancer treatment, through the discovery of targeted therapies that are effective in molecularly defined patients. Cancer is a complex disease and our platform, combining large-scale screening in advanced cancer models and cancer big data, is providing Mosaic with unprecedented clarity and insight.”
Mosaic Therapeutics is the latest spin-out company from the Wellcome Sanger Institute, with notable accomplishments including being the largest single contributor to the Human Genome Project, co-founding the International Cancer Genome Consortium, and identifying specific BRAF mutations that support new classes of targeted cancer therapies.
